FDA grants 'Priority Review' status to Jazz Pharmaceuticals' Xywav

Jazz Pharmaceuticals (NASDAQ:JAZZ) announces that the U.S. FDA has granted Priority Review designation and confirmed the acceptance for substantive review of the supplemental New Drug Application (sNDA) seeking approval for Xywav oral solution in adult patients with idiopathic hypersomnia.